These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 14556674)

  • 1. The role of erythropoietin in the anemia of myelodysplastic syndrome.
    Stein RS
    Clin Lymphoma; 2003 Aug; 4 Suppl 1():S36-40. PubMed ID: 14556674
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adding growth factors or interleukin-3 to erythropoietin has limited effects on anemia of transfusion-dependent patients with myelodysplastic syndromes unresponsive to erythropoietin alone.
    Musto P; Sanpaolo G; D'Arena G; Scalzulli PR; Matera R; Falcone A; Bodenizza C; Perla G; Carotenuto M
    Haematologica; 2001 Jan; 86(1):44-51. PubMed ID: 11146570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of recombinant human erythropoietin combined with granulocyte/ macrophage colony-stimulating factor in the treatment of patients with myelodysplastic syndrome. GM/EPO MDS Study Group.
    Thompson JA; Gilliland DG; Prchal JT; Bennett JM; Larholt K; Nelson RA; Rose EH; Dugan MH
    Blood; 2000 Feb; 95(4):1175-9. PubMed ID: 10666187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An assessment of erythroid response to epoetin alpha as a single agent versus in combination with granulocyte- or granulocyte-macrophage-colony-stimulating factor in myelodysplastic syndromes using a meta-analysis approach.
    Mundle S; Lefebvre P; Vekeman F; Duh MS; Rastogi R; Moyo V
    Cancer; 2009 Feb; 115(4):706-15. PubMed ID: 19152429
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Erythropoiesis-stimulating agents in the treatment of anemia in myelodysplastic syndromes: a meta-analysis.
    Moyo V; Lefebvre P; Duh MS; Yektashenas B; Mundle S
    Ann Hematol; 2008 Jul; 87(7):527-36. PubMed ID: 18351340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Erythropoietin plus granulocyte colony-stimulating factor is better than erythropoietin alone to treat anemia in low-risk myelodysplastic syndromes: results from a randomized single-centre study.
    Balleari E; Rossi E; Clavio M; Congiu A; Gobbi M; Grosso M; Secondo V; Spriano M; Timitilli S; Ghio R
    Ann Hematol; 2006 Mar; 85(3):174-80. PubMed ID: 16408206
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Erythropoietin plus granulocyte colony-stimulating factor in the treatment of myelodysplastic syndromes. Identification of a subgroup of responders. The Spanish Erythropathology Group.
    Remacha AF; Arrizabalaga B; Villegas A; Manteiga R; Calvo T; Julià A; Fernández Fuertes I; González FA; Font L; Juncà J; del Arco A; Malcorra JJ; Equiza EP; de Mendiguren BP; Romero M
    Haematologica; 1999 Dec; 84(12):1058-64. PubMed ID: 10586205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of the anemia of aplastic anemia patients with recombinant human erythropoietin in combination with granulocyte colony-stimulating factor: a multicenter randomized controlled study. Multicenter Study Group.
    Bessho M; Hirashima K; Asano S; Ikeda Y; Ogawa N; Tomonaga M; Toyama K; Nakahata T; Nomura T; Mizoguchi H; Yoshida Y; Niitsu Y; Kohgo Y
    Eur J Haematol; 1997 Apr; 58(4):265-72. PubMed ID: 9186538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant human erythropoietin in combined treatment with granulocyte- or granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes.
    Kasper C; Zahner J; Sayer HG
    J Cancer Res Clin Oncol; 2002 Sep; 128(9):497-502. PubMed ID: 12242514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model.
    Hellström-Lindberg E; Negrin R; Stein R; Krantz S; Lindberg G; Vardiman J; Ost A; Greenberg P
    Br J Haematol; 1997 Nov; 99(2):344-51. PubMed ID: 9375752
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant human erythropoietin in very elderly patients with myelodysplastic syndromes: results from a retrospective study.
    Tatarelli C; Piccioni AL; Maurillo L; Naso V; Battistini R; D'Andrea M; Criscuolo M; Nobile C; Villivà N; Mancini S; Neri B; Breccia M; Fenu S; Buccisano F; Voso MT; Latagliata R; Aloe Spiriti MA
    Ann Hematol; 2014 Aug; 93(8):1413-20. PubMed ID: 24647684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: evidence for in vivo synergy.
    Negrin RS; Stein R; Doherty K; Cornwell J; Vardiman J; Krantz S; Greenberg PL
    Blood; 1996 May; 87(10):4076-81. PubMed ID: 8639764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anemia of hematologic malignancies: what are the treatment options?
    Ludwig H
    Semin Oncol; 2002 Jun; 29(3 Suppl 8):45-54. PubMed ID: 12082654
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Haematopoietic growth factors in the treatment of myelodysplastic syndromes.
    Cazzola M
    Forum (Genova); 1999; 9(1):49-57. PubMed ID: 10101210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome.
    Jädersten M; Malcovati L; Dybedal I; Della Porta MG; Invernizzi R; Montgomery SM; Pascutto C; Porwit A; Cazzola M; Hellström-Lindberg E
    J Clin Oncol; 2008 Jul; 26(21):3607-13. PubMed ID: 18559873
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life.
    Hellström-Lindberg E; Gulbrandsen N; Lindberg G; Ahlgren T; Dahl IM; Dybedal I; Grimfors G; Hesse-Sundin E; Hjorth M; Kanter-Lewensohn L; Linder O; Luthman M; Löfvenberg E; Oberg G; Porwit-MacDonald A; Rådlund A; Samuelsson J; Tangen JM; Winquist I; Wisloff F;
    Br J Haematol; 2003 Mar; 120(6):1037-46. PubMed ID: 12648074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial.
    Casadevall N; Durieux P; Dubois S; Hemery F; Lepage E; Quarré MC; Damaj G; Giraudier S; Guerci A; Laurent G; Dombret H; Chomienne C; Ribrag V; Stamatoullas A; Marie JP; Vekhoff A; Maloisel F; Navarro R; Dreyfus F; Fenaux P
    Blood; 2004 Jul; 104(2):321-7. PubMed ID: 15054036
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant human granulocyte-macrophage colony-stimulating factor plus erythropoietin for the treatment of cytopenias in patients with myelodysplastic syndromes.
    Stasi R; Pagano A; Terzoli E; Amadori S
    Br J Haematol; 1999 Apr; 105(1):141-8. PubMed ID: 10233377
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose darbepoetin alpha in the treatment of anaemia of lower risk myelodysplastic syndrome results of a phase II study.
    Mannone L; Gardin C; Quarre MC; Bernard JF; Vassilieff D; Ades L; Park S; Vaultier S; Hamza F; Beyne-rauzy MO; Cheze S; Giraudier S; Agape P; Legros L; Voillat L; Dreyfus F; Fenaux P;
    Br J Haematol; 2006 Jun; 133(5):513-9. PubMed ID: 16681638
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of the anemia of myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor in combination with erythropoietin.
    Negrin RS; Stein R; Vardiman J; Doherty K; Cornwell J; Krantz S; Greenberg PL
    Blood; 1993 Aug; 82(3):737-43. PubMed ID: 7687889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.